Bartenschlager R,Baumert TF,Bukh J,Houghton M,Lemon SM,Lindenbach BD,Lohmann V,Moradpour D,Pietschmann T,Rice CM,Thimme R CM .2018 .Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res., 15(248) : 53-62.
Calvaruso V,Mazzarelli C,Milazzo L,Badia L,Pasulo L,Guaraldi G,Lionetti R,Villa E,Borghi V,Carrai P,Alberti A .2019 .Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. Sci. Rep, 9(1) : 585.
Carrion AF .2017 .Treatment of HCV in individuals with decompensated cirrhosis. J. Liver Res. Disord. Ther., 3(4) : 00056.
Charlton MR,Gane EJ,Manns MP,Brown RS,Curry MP,Kwo PY,Fontana RJ,Gilroy R,Teperman LW,Muir AJ,McHutchison JG .2013 .Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis c infection after liver transplantation: preliminary results of a prospective, multicenter study: LB-2. , 58(6) : 1378A.
Di Pascoli M,Ceranto E,De Nardi P,Donato D,Gatta A,Angeli P,Pontisso P .2017 .Hospitalizations due to cirrhosis: Clinical aspects in a large cohort of Italian patients and cost analysis report. Digestive Dis, 35(5) : 433-438.
.2016 .EASL recommendations on treatment of hepatitis C. J. , 66(1) : 153-194.
Foster GR,Afdhal N,Roberts SK,Brau N,Gane EJ,Pianko S,Lawitz E,Thompson A,Shiffman ML,Cooper C,Towner WJ C .2015 .Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med, 373(27) : 2608-2617.
Ilyas JA,Vierling JM .2011 .An overview of emerging therapies for the treatment of chronic hepatitis C. C. Clin. , 15(3) : 515-536.
Janiak M,Caraballo Cortés K,Perlejewski K,KubickaRussel D,Grabarczyk P,Demkow U,Radkowski M U .2018 .Next-generation sequencing of hepatitis C virus (HCV) mixed-genotype infections in anti-HCVnegative blood donors. Phys. Ther, : 65-71.
Lanini S,Ustianowski A,Pisapia R,Zumla A,Ippolito G .2019 .Viral hepatitis: Etiology, epidemiology, transmission, diagnostics, treatment and prevention. Infect. Dis. Clin., 33(4) : 1045-1062.
Liu CH,Su TH,Liu CJ,Hong CM,Yang HC,Tseng TC,Chen PJ,Chen DS,Kao JH,Gastroenterol JH .2019 .Sofosbuvir based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. , 34(9) : 1620-1625.
Majumdar A,Kitson MT,Roberts SK .2016 .Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. , 43(12) : 1276-1292.
Pellicelli AM,Montalbano M,Lionetti R,Durand C,Ferenci P,D'Offizi G,Knop V,Telese A,Lenci I,Andreoli A,Zeuzem S A .2014 .Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig. Liver Dis, 46(10) : 923-927.
Pol S,Ghalib RH,Rustgi VK,Martorell C,Everson GT,Tatum HA,Hezode C,Lim JK,Bronowicki JP,Abrams GA,Brau N GA .2012 .Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. The Lancet Inf. Dis., 12(9) : 671-677.
Shah A,Nizamuddin NU,Iqbal W .2018 .Down staging of cirrhosis in all cirrhotic patients with hcv genotype 3-a infection, treated with 12-weeks triple therapy, including sofosbuvir, daclatasvir and ribavirin. InMed. Forum, 3(29) : 3.
Shahid I,Almalki WH,Ibrahim MM,Alghamdi SA,Mukhtar MH,Almalki SSR,Alhaidari MS .2018 .Characterization of in vitro inhibitory effects of consensus short interference RNAs against nonstructural 5B gene of hepatitis C virus 1a genotype. Indian J. Med, 36(4) : 494-503.
Sulkowski MS,Gardiner DF,Rodriguez-Torres M,Reddy KR,Hassanein T,Jacobson I,Lawitz E,Lok AS,Hinestrosa F,Thuluvath PJ,Schwartz H PJ .2014 .Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Eng. J. Med, 370(3) : 211-21.
Thrift AP,El-Serag HB,Kanwal F HB .2017 .Global epidemiology and burden of HCV infection and HCVrelated disease. Nat. Rev. Gastroenterol. Hepatol., 14(2) : 122-132.
Ullah A,Rehman IU,Ahmad J,Gohar M,Ahmad S,Ahmad B .2020 .Hepatitis-C virus and cirrhosis: An overview from Khyber Pakhtunkhwa province of Pakistan. , 33(5) : 396-403.
Ullah A,Rehman IU,Ahmad J,Odenthal M,Ahmad S,Nadeem T,Ali Q,Rizwan M,Khan MA,Hassan S,Ahsan H S .2021 .Phylogenetic analysis of the 5ʹ untranslated region of HCV from cirrhotic patients in Khyber Pakhtunkhwa, Pakistan. , 11(1) : 15023.
Wani MA,Agarwal NB,Khan MA .2022 .Neurocognitive changes in chronic hepatitis c patients receiving combination therapy of interferon and ribavirin: A systematic review. Curr Drug Ther., 17(5) : 349-358.
Welzel TM,Petersen J,Herzer K,Ferenci P,Gschwantler M,Wedemeyer H,Berg T,Spengler U,Weiland O,van der Valk M,Rockstroh J .2016 .Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. , 65(11) : 1861-70.
Zafar A,Imran M,Zahoor S,Shah ZH,Ali M,Afzal MS M .2018 .Prevalence and treatment of untypable HCV variants in different districts of Punjab, Pakistan. , 31(6) : 426-432.
Zeuzem S,Feinman SV,Rasenack J,Heathcote EJ,Lai MY,Gane E,O'Grady J,Reichen J,Diago M,Lin A,Hoffman J .2000 .Peginterferon alfa-2a in patients with chronic hepatitis C. New Eng. J. Med, 343(23) : 1666-1672.